<DOC>
	<DOCNO>NCT00109109</DOCNO>
	<brief_summary>The purpose study : - To determine maximum tolerate dose ( MTD ) SAHA administer every 12 hour 14 consecutive day follow 7 day rest first two cycle ( i.e. , first 6 week ) patient advanced multiple myeloma ; - To assess safety overall response rate SAHA patient advance multiple myeloma .</brief_summary>
	<brief_title>A Clinical Trial Oral Suberoylanilide Hydroxamic Acid ( SAHA ) Patients With Advanced Multiple Myeloma ( 0683-004 )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Adult patient refractory relapse multiple myeloma , ECOG performance status 02 ( ECOG ) Adequate bone marrow reserve Adequate hepatic renal function Ability swallow capsule 3 week prior chemotherapy recover prior toxicity Patients plan go bone marrow transplant within 4 week start treatment Patients prior treatment investigational agent similar antitumor mechanism Patients active/uncontrolled clinically significant illness Pregnant nursing female patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>